Biosimilars and the long game

Biosimilars and the long game

Despite greater certainty for biosimilar markets and regulation, the change that was seen in the small-molecule pharmaceuticals market with the rapid entrance of emerging-country generics suppliers will not be replicated exactly. The long game has yet to be played out, and recent changes in regulati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Trends in biotechnology (Regular ed.) 2015-05, Vol.33 (5), p.250-252
Hauptverfasser: Huzair, Farah, Kale, Dinar
Format: Artikel
Sprache:eng
Schlagworte:
Biological products
biosimilar
Biosimilar Pharmaceuticals
Biotechnology
Clinical trials
Control
Cost control
Decision making
Drug and Narcotic Control - trends
Drug Design
Drug Industry - trends
Entrances
Flexibility
follow-on biologic
Games
Generic drugs
Internal Medicine
Manufacturers
Manufacturing
Markets
Medicine
Oncology
Partnerships
Patient safety
Pharmaceutical industry
Regulation
Science
subsequent entry biologic
Suppliers
Trends
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Despite greater certainty for biosimilar markets and regulation, the change that was seen in the small-molecule pharmaceuticals market with the rapid entrance of emerging-country generics suppliers will not be replicated exactly. The long game has yet to be played out, and recent changes in regulation, science, and production technology are likely to impact on future patterns of partnership and production.
ISSN:0167-7799
1879-3096
DOI:10.1016/j.tibtech.2015.01.001